Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout [Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Seguridad y Eficacia de RDEA 594 en comparación con Placebo en el Tratamiento de la Hiperuricemia en Pacientes con Gota]

Trial Profile

Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout [Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Seguridad y Eficacia de RDEA 594 en comparación con Placebo en el Tratamiento de la Hiperuricemia en Pacientes con Gota]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2012

At a glance

  • Drugs Lesinurad (Primary)
  • Indications Gout; Hyperuricaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2011 Results (n=96) presented at the 112th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 04 Mar 2011 Planned end date is 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 19 Jun 2010 Phase 2b monotherapy study results presented at the 11th Annual Congress of the European League Against Rheumatism, according to an Ardea Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top